The injection of naked TriMix mRNA (caTLR4 and co-stimulatory ligands CD70 and CD40L; as described above) directly into the tumor resulted in systemic therapeutic anti-tumor activity in various mouse models and led to a phase I clinical trial in patients with early, resectable breast cancer lesions (NCT03788083) [206]. Here, CD40LG is linked to neoplasm.